Nifty
Sensex
:
:
9837.40
31524.68
-66.75 (-0.67%)
-270.78 (-0.85%)

Pharmaceuticals & Drugs

Rating :
34/99

BSE: 506690 | NSE: UNICHEMLAB

248.80
-2.50 (-0.99%)
18-Aug-2017 | 3:57PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  • 249.95
  • 250.60
  • 246.10
  • 251.30
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  • 13873
  • 34.52
  • 328.00
  • 233.25

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 2,255.30
  • 28.34
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 2,337.22
  • 1.21%
  • 1.99

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 50.06%
  • 7.35%
  • 23.01%
  • FII
  • DII
  • Others
  • 0.08%
  • 12.94%
  • 6.56%

Chart

Price | P:E | P:BV | EV:EBITDA

Quarterly Results

Standalone Figures in Rs. Crores

Description
Mar 17
Mar 16
Var%
Dec 16
Dec 15
Var%
Sep 16
Sep 15
Var%
Jun 16
Jun 15
Var%
Net Sales
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
EBITDA
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
EBIDTM
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
Other Income
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Depreciation
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PBT
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PAT
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PATM
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
EPS
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Net Sales
1,519.50
1,332.65
1,201.79
1,133.45
1,080.80
875.46
824.04
747.39
735.23
671.35
Net Sales Growth
14.02%
10.89%
6.03%
4.87%
23.46%
6.24%
10.26%
1.65%
9.52%
 
Cost Of Goods Sold
442.72
386.97
378.57
332.84
343.06
278.55
237.98
225.17
244.13
256.57
Gross Profit
1,076.78
945.67
823.23
800.61
737.75
596.91
586.07
522.22
491.10
414.77
GP Margin
70.86%
70.96%
68.50%
70.63%
68.26%
68.18%
71.12%
69.87%
66.80%
61.78%
Total Expenditure
1,340.90
1,168.77
1,100.79
955.75
910.06
759.42
674.08
576.53
593.04
584.99
Power & Fuel Cost
46.13
38.25
39.39
35.97
31.36
26.22
22.50
16.23
15.00
14.64
% Of Sales
3.04%
2.87%
3.28%
3.17%
2.90%
2.99%
2.73%
2.17%
2.04%
2.18%
Employee Cost
300.09
255.92
223.20
187.37
164.88
140.06
123.99
99.31
95.96
91.38
% Of Sales
19.75%
19.20%
18.57%
16.53%
15.26%
16.00%
15.05%
13.29%
13.05%
13.61%
Manufacturing Exp.
174.59
150.54
145.03
137.05
119.15
101.54
102.67
77.15
78.86
89.25
% Of Sales
11.49%
11.30%
12.07%
12.09%
11.02%
11.60%
12.46%
10.32%
10.73%
13.29%
General & Admin Exp.
162.94
167.66
153.29
127.77
104.73
88.54
79.74
71.83
71.35
49.91
% Of Sales
10.72%
12.58%
12.76%
11.27%
9.69%
10.11%
9.68%
9.61%
9.70%
7.43%
Selling & Distn. Exp.
212.35
166.84
157.12
134.03
135.93
116.00
106.52
80.88
80.92
75.60
% Of Sales
13.97%
12.52%
13.07%
11.82%
12.58%
13.25%
12.93%
10.82%
11.01%
11.26%
Miscellaneous Exp.
2.06
2.58
4.19
0.73
10.97
8.50
0.70
5.96
6.83
75.60
% Of Sales
0.14%
0.19%
0.35%
0.06%
1.01%
0.97%
0.08%
0.80%
0.93%
1.14%
EBITDA
178.60
163.88
101.00
177.70
170.74
116.04
149.96
170.86
142.19
86.36
EBITDA Margin
11.75%
12.30%
8.40%
15.68%
15.80%
13.25%
18.20%
22.86%
19.34%
12.86%
Other Income
11.02
19.11
20.72
42.38
16.96
12.50
8.32
7.98
10.13
7.46
Interest
3.37
2.90
3.04
3.19
3.29
4.08
2.39
2.38
2.56
2.19
Depreciation
45.18
38.79
41.27
45.72
38.34
30.43
29.22
23.21
22.41
18.14
PBT
141.07
141.31
77.41
171.17
146.07
94.03
126.66
153.24
127.36
73.48
Tax
32.58
29.30
2.13
43.00
32.85
22.77
31.68
30.43
19.20
16.75
Tax Rate
23.09%
21.27%
2.75%
25.12%
22.49%
24.22%
25.01%
19.86%
15.08%
24.59%
PAT
108.49
108.48
75.28
128.16
113.23
71.26
94.98
122.81
108.16
51.39
PAT before Minority Interest
108.49
108.48
75.28
128.16
113.23
71.26
94.98
122.81
108.16
51.39
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
7.14%
8.14%
6.26%
11.31%
10.48%
8.14%
11.53%
16.43%
14.71%
7.65%
PAT Growth
0.01%
44.10%
-41.26%
13.19%
58.90%
-24.97%
-22.66%
13.54%
110.47%
 
Unadjusted EPS
11.92
11.86
8.31
18.69
12.52
7.89
10.53
34.14
29.97
14.26

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Shareholder's Funds
1,063.62
954.33
867.52
816.61
727.07
660.58
617.70
562.92
484.45
411.52
Share Capital
18.18
18.17
18.15
18.13
18.09
18.06
18.05
18.03
18.03
18.02
Total Reserves
1,044.00
935.01
848.52
797.74
707.98
641.80
598.85
544.19
464.39
392.10
Non-Current Liabilities
64.49
76.02
74.21
97.72
94.31
92.67
87.44
70.46
72.10
56.59
Secured Loans
0.44
22.98
20.35
24.65
20.89
20.47
19.01
15.29
20.95
6.49
Unsecured Loans
0.00
0.00
0.00
0.00
0.00
23.49
22.72
20.48
18.78
17.83
Long Term Provisions
25.33
12.58
8.88
7.64
9.19
10.24
7.90
0.00
0.00
0.00
Current Liabilities
455.81
275.09
211.76
230.32
251.12
233.30
176.15
165.34
146.30
134.84
Trade Payables
218.03
163.95
138.23
150.52
156.63
140.30
109.99
115.14
101.30
90.05
Other Current Liabilities
68.01
60.56
45.86
32.99
36.65
34.28
26.00
14.56
15.77
11.15
Short Term Borrowings
97.62
12.93
1.63
1.04
6.17
25.42
9.04
0.00
0.00
0.00
Short Term Provisions
72.15
37.65
26.05
45.78
51.67
33.30
31.13
35.64
29.23
33.64
Total Liabilities
1,583.92
1,305.44
1,153.49
1,144.65
1,072.50
986.55
881.29
798.72
702.85
602.95
Net Block
491.00
402.60
415.99
419.29
447.76
408.39
377.31
333.35
300.81
238.21
Gross Block
565.36
439.53
724.65
688.25
675.87
599.27
537.04
464.60
414.13
333.01
Accumulated Depreciation
74.35
36.92
308.66
268.96
228.11
190.87
159.73
131.25
113.31
94.80
Non Current Assets
760.03
673.34
589.07
563.97
594.06
547.20
456.50
396.26
376.76
341.48
Capital Work in Progress
249.98
237.13
122.64
90.54
132.20
112.76
62.87
62.88
75.93
103.19
Non Current Investment
5.72
5.54
5.83
5.72
5.72
0.03
0.03
0.03
0.02
0.08
Long Term Loans & Adv.
13.33
28.05
44.61
48.42
8.38
26.02
16.29
0.00
0.00
0.00
Other Non Current Assets
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Current Assets
823.89
632.11
564.42
580.68
478.44
439.35
424.79
402.46
326.08
261.46
Current Investments
8.00
8.04
35.04
5.67
33.06
14.50
21.29
59.18
1.00
0.00
Inventories
281.71
230.57
207.68
203.49
143.05
157.96
150.26
107.54
103.39
83.28
Sundry Debtors
320.49
220.09
191.58
196.51
206.95
183.25
185.13
166.97
151.59
139.93
Cash & Bank
16.14
20.13
26.96
52.15
24.64
23.23
15.16
23.64
34.37
10.05
Other Current Assets
197.55
30.51
20.92
17.19
70.75
60.40
52.95
45.13
35.73
28.20
Short Term Loans & Adv.
170.98
122.77
82.25
105.67
61.73
53.14
47.14
45.13
35.73
28.20
Net Current Assets
368.08
357.02
352.66
350.36
227.32
206.05
248.65
237.12
179.78
126.62
Total Assets
1,583.92
1,305.45
1,153.49
1,144.65
1,072.50
986.55
881.29
798.72
702.84
602.94

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Mar 07
Cash From Operating Activity
111.91
78.10
86.73
171.23
124.08
68.59
129.10
102.77
70.03
46.79
PBT
137.68
77.41
171.17
146.07
94.03
126.66
153.24
127.36
68.13
88.09
Adjustment
39.65
35.57
18.74
47.15
39.37
27.54
25.31
25.49
24.23
12.79
Changes in Working Capital
-34.16
-16.49
-66.32
13.05
13.51
-54.81
-21.95
-29.70
-11.21
-42.22
Cash after chg. in Working capital
143.16
96.49
123.58
206.27
146.91
99.39
156.60
123.14
81.15
58.66
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-31.25
-18.39
-36.85
-35.04
-22.83
-30.81
-27.50
-20.37
-11.12
-11.87
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-85.33
-52.34
35.70
-118.45
-101.80
-47.60
-100.15
-57.94
-82.25
-60.72
Net Fixed Assets
154.89
-73.58
38.14
-92.98
-106.47
-67.03
-39.23
-45.49
-80.05
-81.78
Net Investments
42.09
-32.73
20.34
-34.14
-5.98
28.17
-67.50
-19.00
-5.19
-9.13
Others
-282.31
53.97
-22.78
8.67
10.65
-8.74
6.58
6.55
2.99
30.19
Cash from Financing Activity
-33.42
-50.95
-94.92
-51.38
-14.21
-29.46
-39.68
-20.52
-4.91
-45.31
Net Cash Inflow / Outflow
-6.84
-25.19
27.51
1.41
8.07
-8.48
-10.73
24.31
-17.13
-59.24
Opening Cash & Equivalents
26.96
52.15
24.64
23.23
15.16
23.64
34.37
10.05
27.19
86.43
Closing Cash & Equivalent
20.13
26.96
52.15
24.64
23.23
15.16
23.64
34.36
10.05
27.19

Financial Ratios

Consolidated /

Standalone
Description
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Book Value (Rs.)
116.88
104.93
95.48
90.02
80.27
73.06
68.36
62.36
53.52
45.52
ROA
7.51%
8.82%
6.55%
11.56%
11.00%
7.63%
11.31%
16.36%
16.57%
8.84%
ROE
10.77%
11.92%
8.95%
16.62%
16.34%
11.16%
16.11%
23.51%
24.24%
13.01%
ROCE
13.42%
14.97%
9.29%
21.84%
20.13%
14.03%
20.37%
27.72%
27.06%
16.68%
Fixed Asset Turnover
3.06
2.32
1.71
1.67
1.71
1.55
1.66
1.71
1.99
2.20
Receivable days
64.25
55.72
58.55
64.53
65.42
76.34
77.46
77.49
71.68
75.09
Inventory Days
60.89
59.32
62.03
55.42
50.47
63.88
56.72
51.31
45.90
44.74
Payable days
56.76
52.00
52.61
62.52
65.77
65.64
63.82
75.73
62.75
61.87
Cash Conversion Cycle
68.38
63.05
67.97
57.43
50.11
74.58
70.36
53.06
54.83
57.97
Total Debt/Equity
0.09
0.04
0.03
0.03
0.04
0.11
0.08
0.06
0.08
0.06
Interest Cover
42.87
48.57
26.45
54.66
45.40
24.06
53.94
65.29
50.85
32.04

News Update


  • Unichem receives ANDA approval for Losartan Potassium, Hydrochlorothiazide tablets
    25th Jul 2017, 11:20 AM

    The product will be commercialized from Unichem’s Ghaziabad plant

    Read More
  • Unichem Laboratories receives EIR from USFDA for Goa facility
    30th Jun 2017, 10:11 AM

    This receipt indicates the successful closure of the inspection and the queries raised during the audit

    Read More
  • Unichem plans Rs 350 crore capex for next two years
    9th Jun 2017, 10:39 AM

    The long term aim of the company is to cross $500 million in revenues from the US operations

    Read More
  • Unichem Laboratories’ Ghaziabad facility receives EIR from USFDA
    7th Jun 2017, 10:08 AM

    The inspection was carried out between February 24, 2017 to March 3, 2017

    Read More
  • Unichem Lab - Quarterly Results
    30th May 2017, 12:00 AM

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.